F
Firebrick Pharma Ltd
ASX:FRE
Firebrick Pharma Ltd
ASX:FRE
Price:
0.059
AUD
3.51%
Market Closed
Market Cap:
AU$14.9m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
F
|
Firebrick Pharma Ltd
ASX:FRE
|
AU |
|
Datametrex AI Ltd
XTSX:DM
|
CA |
|
Neogrid Participacoes SA
BOVESPA:NGRD3
|
BR |
|
Renrenle Commercial Group Co Ltd
SZSE:002336
|
CN |
|
W
|
Wang Zheng Bhd
KLSE:WANGZNG
|
MY |
Cash Flow Statement
Cash Flow Statement
Firebrick Pharma Ltd
Firebrick Pharma Ltd
Currency: AUD
| Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | |||||||||
| Stock-Based Compensation |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Change in Working Capital |
(3)
|
(4)
|
(4)
|
(4)
|
(2)
|
(1)
|
(1)
|
(1)
|
|
| Cash from Operating Activities |
(4)
N/A
|
(5)
-21%
|
(6)
-14%
|
(5)
+20%
|
(2)
+49%
|
(2)
+18%
|
(2)
+8%
|
(2)
-26%
|
|
| Investing Cash Flow | |||||||||
| Capital Expenditures |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Cash from Investing Activities |
(0)
N/A
|
(0)
+49%
|
(0)
+90%
|
(0)
+94%
|
(0)
N/A
|
(0)
-66 400%
|
(0)
-25%
|
(0)
+80%
|
|
| Financing Cash Flow | |||||||||
| Net Issuance of Common Stock |
11
|
7
|
1
|
1
|
1
|
2
|
2
|
3
|
|
| Net Issuance of Debt |
0
|
(0)
|
0
|
(0)
|
0
|
0
|
0
|
0
|
|
| Other |
(0)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
0
|
|
| Cash from Financing Activities |
10
N/A
|
6
-44%
|
1
-82%
|
1
+0%
|
1
-18%
|
2
+96%
|
2
+27%
|
3
+38%
|
|
| Change in Cash | |||||||||
| Net Change in Cash |
6
N/A
|
1
-90%
|
(5)
N/A
|
(4)
+25%
|
(2)
+58%
|
(0)
+74%
|
0
N/A
|
1
+234%
|
|
| Free Cash Flow | |||||||||
| Free Cash Flow |
(4)
N/A
|
(5)
-20%
|
(6)
-14%
|
(5)
+20%
|
(2)
+49%
|
(2)
+15%
|
(2)
+7%
|
(2)
-21%
|
|
Switch to:
Switch to:
See Also
Discover More
